Epithelial ovarian cancer is the leading cause of death among gynecologic malignancies, and two thirds of patients present with stages III and IV disease. Standard first-line therapy for ovarian cancer includes cytoreductive surgery followed by combination platinum/taxaneYbased chemotherapy and yields impressive response rates of 75% to 80%.1 The addition of intraperitoneal chemotherapies improved median overall sur- vival to E?65 months, representing a significant improvement in the last 20 years.2,3